DNA methyltransferase inhibitor exposure–response: Challenges and opportunities
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DNA methyltransferase inhibitor exposure–response: Challenges and opportunities
Authors
Keywords
-
Journal
CTS-Clinical and Translational Science
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-06-24
DOI
10.1111/cts.13548
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomised phase II study of azacitidine ( AZA ) alone or with Lenalidomide ( LEN ), Valproic acid ( VPA ) or Idarubicin ( IDA ) in higher‐Risk MDS or low blast AML : GFM 's “pick a winner” trial, with the impact of somatic mutations
- (2022) Lionel Adès et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy
- (2022) Theodoros Karantanos et al. LEUKEMIA & LYMPHOMA
- Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
- (2022) Pau Montesinos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
- (2022) Laurence C. Cheung et al. LEUKEMIA
- Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
- (2021) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Meaningful response criteria for myelodysplastic syndromes
- (2021) Nina Kim et al. BRITISH JOURNAL OF HAEMATOLOGY
- Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML
- (2020) Guillermo Garcia-Manero et al. BLOOD
- A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs
- (2020) Enrico Girardi et al. Nature Chemical Biology
- Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia
- (2020) Emily Gruber et al. LEUKEMIA
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action
- (2020) Ellen J. B. Derissen et al. CLINICAL PHARMACOKINETICS
- Current and emerging strategies for management of myelodysplastic syndromes
- (2020) Caner Saygin et al. BLOOD REVIEWS
- Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
- (2020) Andrew H. Wei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
- (2020) Rami S. Komrokji et al. Cancer Medicine
- Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
- (2019) Jing Nie et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3 -ITD Mutated Acute Myeloid Leukemia (AML)
- (2018) Maro Ohanian et al. AMERICAN JOURNAL OF HEMATOLOGY
- CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
- (2018) Marcos de Lima et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
- (2018) Matthieu Duchmann et al. EBioMedicine
- Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular β-decitabine nucleotides and genomic DNA incorporated β-decitabine and 5-methyl-2′-deoxycytidine
- (2018) Jeroen Roosendaal et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo
- (2017) A Unnikrishnan et al. LEUKEMIA
- Hypomethylation agent decitabine restores drug sensitivity by depressing P-glycoprotein activity through MAPK signaling pathway
- (2017) Huihan Wang et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Epigenetics of hematopoiesis and hematological malignancies
- (2016) Deqing Hu et al. GENES & DEVELOPMENT
- Simultaneous quantitative determination of 5-aza-2′-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors
- (2016) Nicole M. Anders et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome
- (2016) Lingyun Wu et al. Journal of Translational Medicine
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- The complexity of interpreting genomic data in patients with acute myeloid leukemia
- (2016) A Nazha et al. Blood Cancer Journal
- Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
- (2016) Koichi Takahashi et al. Oncotarget
- Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia
- (2015) Ashkan Emadi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cellular Uptake of Decitabine by Equilibrative Nucleoside Transporters in HCT116 Cells
- (2015) Kumiko Ueda et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine
- (2015) Nicole M. Anders et al. BIOMEDICAL CHROMATOGRAPHY
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome
- (2015) Ping Wu et al. LEUKEMIA RESEARCH
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
- (2014) R. Bejar et al. BLOOD
- Predicting response to epigenetic therapy
- (2014) Marianne B. Treppendahl et al. JOURNAL OF CLINICAL INVESTIGATION
- Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells
- (2014) Simin Öz et al. NUCLEIC ACIDS RESEARCH
- Genomic impact of transient low-dose decitabine treatment on primary AML cells
- (2013) J. M. Klco et al. BLOOD
- Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry
- (2013) Ellen J.B. Derissen et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
- (2013) F Traina et al. LEUKEMIA
- Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
- (2013) A Valencia et al. LEUKEMIA
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Concise Drug Review: Azacitidine and Decitabine
- (2013) E. J. B. Derissen et al. ONCOLOGIST
- In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia
- (2012) Hongyan Wang et al. AAPS Journal
- ABC transporters and their role in nucleoside and nucleotide drug resistance
- (2012) Yu Fukuda et al. BIOCHEMICAL PHARMACOLOGY
- RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia
- (2012) J. Aimiuwu et al. BLOOD
- Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study
- (2012) Robert S. Jansen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Epigenetic Resensitization to Platinum in Ovarian Cancer
- (2012) D. Matei et al. CANCER RESEARCH
- Role of Human Nucleoside Transporters in the Uptake and Cytotoxicity of Azacitidine and Decitabine
- (2012) Vijaya L. Damaraju et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named p
- (2011) Lieke H. van der Helm et al. BRITISH JOURNAL OF HAEMATOLOGY
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
- (2011) Lewis R. Silverman et al. CANCER
- Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
- (2011) Thomas Prébet et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
- (2011) Taichun Qin et al. PLoS One
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
- (2010) R. Itzykson et al. BLOOD
- Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
- (2010) Elias Jabbour et al. CANCER
- Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes
- (2010) John F. Seymour et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Vectorial Transport of Nucleoside Analogs from the Apical to the Basolateral Membrane in Double-Transfected Cells Expressing the Human Concentrative Nucleoside Transporter hCNT3 and the Export Pump ABCC4
- (2010) M. Rius et al. DRUG METABOLISM AND DISPOSITION
- Chemical Decomposition of 5-Aza-2′-deoxycytidine (Decitabine): Kinetic Analyses and Identification of Products by NMR, HPLC, and Mass Spectrometry
- (2009) Daniel K. Rogstad et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
- (2009) Roger M. Lyons et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
- (2009) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
- (2009) Lanlan Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation
- (2009) M. Rius et al. MOLECULAR CANCER THERAPEUTICS
- Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies
- (2008) Katan Patel et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Azacytidine causes complex DNA methylation responses in myeloid leukemia
- (2008) C. Stresemann et al. MOLECULAR CANCER THERAPEUTICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started